Snapshot of Survival will make its Miami premiere at the University of Miami Sylvester Comprehensive Cancer Center. Snapshot is an art exhibit and contest for people who have been affected by colorectal cancer -- not only patients, but their families and friends. The entries are meant to be a way for people to express the power of survival and their hope for the future. In fact, artwork is considered an important component of the healing process by many people.
Aaron H. Wolfson, UM/Sylvester Radiation Oncologist, UM/Jackson Cancer Committee Chair, and professor and vice chair of the Department of Radiation Oncology at the University of Miami Leonard M. Miller School of Medicine, has been elected to serve on the Board of Directors of the Gynecologic Oncology Group. The Gynecologic Oncology Group (GOG), which receives support from the National Institutes of Health, promotes excellence and quality in clinical and basic scientific research in the field of gynecologic malignancies.
Researchers from the University of Miami Miller School of Medicine surveyed students at a Miami-Dade County public high school and found white Hispanic teens were more likely to use tanning beds and less likely to consider themselves at risk for skin cancer or protect themselves from the sun than white non-Hispanic teens. The findings were published in the August issue of Archives of Dermatology, one of the JAMA/Archives journals.*
Harcourt Sylvester, Jr., whose generosity and drive founded the University of Miami Sylvester Comprehensive Cancer Center, died on April 10, 2007. He was 80.
Juan Carlos Ramos, M.D., member of the Viral Oncology Program at UM/Sylvester and assistant professor of clinical medicine, Division of Hematology-Oncology at the University of Miami Leonard M. Miller School of Medicine, is one of only five researchers in the nation to receive a prestigious Damon Runyon Clinical Investigator Award. The award will support his groundbreaking work on the role of an oncogenic protein in adult T-cell leukemia/lymphoma (ATLL). Ramos’s work promises to help predict which patients will respond to interferon-based therapy so that all ATLL patients receive the best treatment soon after diagnosis.